{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-337944","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2026-08-06T20:05:18+00:00","discovered_at":"2026-08-06T20:06:00.432995+00:00","generated_at":"2026-08-06T20:06:20.312779+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IN8bio reports Q2 2026 net loss of $4.8M; advances gamma-delta TCE platform with in vivo data expected H2 2026","bullets":["Net loss of $4.8M ($0.25 per share) in Q2 2026, improved from $5.1M ($1.24) in Q2 2025.","Cash of $18.0M at June 30, 2026, up from $13.2M a year earlier.","DeltEx DRI in GBM: mOS >19.5 months, mPFS 13.0 months vs 6.6 months SOC.","INB-619 gamma-delta TCE platform advancing; initial in vivo data expected H2 2026.","Peer-reviewed publication in JCO and updated data at ASCO 2026 for DeltEx DRI in GBM."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-337944","json":"https://secwatch.observer/filing/0001193125-26-337944.json","markdown":"https://secwatch.observer/filing/0001193125-26-337944.md","text":"https://secwatch.observer/filing/0001193125-26-337944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/0001193125-26-337944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/inab-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:06:20.312779+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}